Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | PTPRB | P23467 | 1/20 | 0.31 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL292353 | 0.86 | AKT1 (0.44) | AKT1AAK1SCN9ACTSSCTSK | |
| SCHEMBL293844 | 0.84 | AKT1 (0.47) | AKT1AAK1CTSSMEN1KMT2A | |
| SCHEMBL291831 | 0.81 | AKT1 (0.46) | AKT1AAK1CTSSMEN1KMT2A | |
| SCHEMBL291652 | 0.80 | AKT1 (0.39) | AKT1AAK1CTSSCTSK | |
| SCHEMBL291873 | 0.80 | AKT1 (0.53) | AKT1AAK1CTSSCTSKSMN1; SMN2 | |
| SCHEMBL292362 | 0.77 | AKT1 (0.38) | AKT1AAK1 | |
| SCHEMBL291187 | 0.77 | AKT1 (0.50) | AKT1CTSSMEN1KMT2A | |
| SCHEMBL291848 | 0.72 | SMN1; SMN2 (0.43) | AAK1SCN9ACTSSCTSKSMN1; SMN2 | |
| SCHEMBL14291898 | 0.69 | HSD17B1 (0.44) | CTSSCTSKSMN1; SMN2MEN1KMT2A | |
| SCHEMBL293665 | 0.68 | LATS1 (0.41) | AAK1SCN9ACTSSCTSKNLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158790-B2 | Cyclic amine compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-04-17 | — | — | US | disclosed |
| EP-2036896-B1 | CYCLIC AMINE COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2012-03-14 | — | — | EP | disclosed |
| US-20090286807-A1 | CYCLIC AMINE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2036896-A1 | CYCLIC AMINE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286807-A1 | CYCLIC AMINE COMPOUND | HRH3, HRH4, H1-0 | AKT1 2749/4885AAK1 3037/4885SCN9A 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.